A detailed history of Royal Bank Of Canada transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 29,107 shares of RVNC stock, worth $74,804. This represents 0.0% of its overall portfolio holdings.

Number of Shares
29,107
Previous 28,442 2.34%
Holding current value
$74,804
Previous $73,000 1.37%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.57 - $2.57 $1,709 - $1,709
665 Added 2.34%
29,107 $74,000
Q2 2024

Aug 14, 2024

SELL
$2.34 - $4.73 $155,167 - $313,651
-66,311 Reduced 69.98%
28,442 $73,000
Q1 2024

Nov 05, 2024

BUY
$4.65 - $9.31 $308,346 - $617,355
66,311 Added 233.14%
94,753 $466,000
Q1 2024

May 15, 2024

BUY
$4.65 - $9.31 $25,226 - $50,506
5,425 Added 6.07%
94,753 $466,000
Q4 2023

Feb 14, 2024

BUY
$5.81 - $11.2 $99,147 - $191,128
17,065 Added 23.62%
89,328 $785,000
Q3 2023

Nov 14, 2023

BUY
$11.47 - $25.07 $338,972 - $740,893
29,553 Added 69.19%
72,263 $828,000
Q2 2023

Aug 14, 2023

SELL
$24.7 - $37.61 $27,244 - $41,483
-1,103 Reduced 2.52%
42,710 $1.08 Million
Q1 2023

May 15, 2023

SELL
$18.36 - $35.27 $364,978 - $701,132
-19,879 Reduced 31.21%
43,813 $1.41 Million
Q4 2022

Feb 14, 2023

BUY
$18.32 - $30.66 $207,382 - $347,071
11,320 Added 21.61%
63,692 $1.18 Million
Q3 2022

Nov 14, 2022

SELL
$14.33 - $28.47 $301,861 - $599,720
-21,065 Reduced 28.68%
52,372 $1.41 Million
Q2 2022

Aug 15, 2022

BUY
$11.52 - $20.4 $195,528 - $346,249
16,973 Added 30.06%
73,437 $1.01 Million
Q1 2022

May 16, 2022

SELL
$12.36 - $20.31 $4,956 - $8,144
-401 Reduced 0.71%
56,464 $1.1 Million
Q4 2021

Feb 14, 2022

BUY
$12.46 - $27.87 $190,401 - $425,881
15,281 Added 36.75%
56,865 $928,000
Q3 2021

Nov 15, 2021

BUY
$25.78 - $33.21 $437,512 - $563,606
16,971 Added 68.95%
41,584 $1.16 Million
Q2 2021

Aug 16, 2021

BUY
$26.8 - $31.84 $659,628 - $783,677
24,613 New
24,613 $730,000

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.